Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

28 of 40

Shawn McCarthy, CEO of Tryton Medical

Venture capital funding in the medical device world hasn't exactly been soaring since the 2008 downturn, but the crash and the tepid VC climate that ensued have taught startups a valuable lesson, Tryton Medical CEO Shawn McCarthy said: It's just as important to establish economic viability as clinical effectiveness. McCarthy's company closed a $24 million fundraising round this week, money that will take its novel stent all the way through the FDA process, he said. To woo investors, Tryton established the broad unmet need for the device, McCarthy said, because "all of the stakeholders need to see a benefit--patients, doctors, hospitals and, of course, payers."